PCSK9 aggravated carotid artery stenosis in ApoE-/- mice by promoting the expression of tissue factors in endothelial cells via the TLR4/NF-κB pathway

[Display omitted] Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play a significant role in the development of atherosclerosis. In this chronic inflammatory environment, we aimed to investigate whether PCSK9 co...

Full description

Saved in:
Bibliographic Details
Published inBiochemical pharmacology Vol. 225; p. 116314
Main Authors Peng, Chao, Li, Jian, Chen, Yan, Zhang, Heng-rui, Li, Tian-xing, Jiang, Yu-hang, Yang, Xin-yu, Zhao, Yan
Format Journal Article
LanguageEnglish
Published England Elsevier Inc 01.07.2024
Subjects
Online AccessGet full text
ISSN0006-2952
1873-2968
1873-2968
DOI10.1016/j.bcp.2024.116314

Cover

Abstract [Display omitted] Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play a significant role in the development of atherosclerosis. In this chronic inflammatory environment, we aimed to investigate whether PCSK9 could mitigate atherosclerosis progression by reducing tissue factor expression in ECs via in vivo and in vitro assays. In vivo, we investigated the effect of PCSK9 inhibition on preventing atherosclerotic lesion formation in ApoE-/- mice fed a western diet. The results showed that inhibiting PCSK9 could significantly downregulate the protein expression of tissue factor (TF) in ECs to reduce the area of atherosclerotic plaques. In vitro, we incubated human umbilical vein endothelial cells (HUVECs) with lipopolysaccharide (LPS). We found that LPS-induced TF elevation was suppressed by a PCSK9 inhibitor at both the mRNA and protein levels and that the TLR4/NF-κB pathway was also suppressed by a PCSK9 inhibitor. With respect to plasma samples from patients with carotid artery stenosis, we also demonstrated that the expression of TF was positively correlated with that of PCSK9. Thus, in addition to regulating lipid metabolism, the regulation of endothelial cell TF expression through the TLR4/NF-κB pathway may be a potential mechanism of PCSK9 in promoting atherosclerotic carotid stenosis.
AbstractList Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play a significant role in the development of atherosclerosis. In this chronic inflammatory environment, we aimed to investigate whether PCSK9 could mitigate atherosclerosis progression by reducing tissue factor expression in ECs via in vivo and in vitro assays. In vivo, we investigated the effect of PCSK9 inhibition on preventing atherosclerotic lesion formation in ApoE-/- mice fed a western diet. The results showed that inhibiting PCSK9 could significantly downregulate the protein expression of tissue factor (TF) in ECs to reduce the area of atherosclerotic plaques. In vitro, we incubated human umbilical vein endothelial cells (HUVECs) with lipopolysaccharide (LPS). We found that LPS-induced TF elevation was suppressed by a PCSK9 inhibitor at both the mRNA and protein levels and that the TLR4/NF-κB pathway was also suppressed by a PCSK9 inhibitor. With respect to plasma samples from patients with carotid artery stenosis, we also demonstrated that the expression of TF was positively correlated with that of PCSK9. Thus, in addition to regulating lipid metabolism, the regulation of endothelial cell TF expression through the TLR4/NF-κB pathway may be a potential mechanism of PCSK9 in promoting atherosclerotic carotid stenosis.Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play a significant role in the development of atherosclerosis. In this chronic inflammatory environment, we aimed to investigate whether PCSK9 could mitigate atherosclerosis progression by reducing tissue factor expression in ECs via in vivo and in vitro assays. In vivo, we investigated the effect of PCSK9 inhibition on preventing atherosclerotic lesion formation in ApoE-/- mice fed a western diet. The results showed that inhibiting PCSK9 could significantly downregulate the protein expression of tissue factor (TF) in ECs to reduce the area of atherosclerotic plaques. In vitro, we incubated human umbilical vein endothelial cells (HUVECs) with lipopolysaccharide (LPS). We found that LPS-induced TF elevation was suppressed by a PCSK9 inhibitor at both the mRNA and protein levels and that the TLR4/NF-κB pathway was also suppressed by a PCSK9 inhibitor. With respect to plasma samples from patients with carotid artery stenosis, we also demonstrated that the expression of TF was positively correlated with that of PCSK9. Thus, in addition to regulating lipid metabolism, the regulation of endothelial cell TF expression through the TLR4/NF-κB pathway may be a potential mechanism of PCSK9 in promoting atherosclerotic carotid stenosis.
[Display omitted] Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play a significant role in the development of atherosclerosis. In this chronic inflammatory environment, we aimed to investigate whether PCSK9 could mitigate atherosclerosis progression by reducing tissue factor expression in ECs via in vivo and in vitro assays. In vivo, we investigated the effect of PCSK9 inhibition on preventing atherosclerotic lesion formation in ApoE-/- mice fed a western diet. The results showed that inhibiting PCSK9 could significantly downregulate the protein expression of tissue factor (TF) in ECs to reduce the area of atherosclerotic plaques. In vitro, we incubated human umbilical vein endothelial cells (HUVECs) with lipopolysaccharide (LPS). We found that LPS-induced TF elevation was suppressed by a PCSK9 inhibitor at both the mRNA and protein levels and that the TLR4/NF-κB pathway was also suppressed by a PCSK9 inhibitor. With respect to plasma samples from patients with carotid artery stenosis, we also demonstrated that the expression of TF was positively correlated with that of PCSK9. Thus, in addition to regulating lipid metabolism, the regulation of endothelial cell TF expression through the TLR4/NF-κB pathway may be a potential mechanism of PCSK9 in promoting atherosclerotic carotid stenosis.
Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play a significant role in the development of atherosclerosis. In this chronic inflammatory environment, we aimed to investigate whether PCSK9 could mitigate atherosclerosis progression by reducing tissue factor expression in ECs via in vivo and in vitro assays. In vivo, we investigated the effect of PCSK9 inhibition on preventing atherosclerotic lesion formation in ApoE mice fed a western diet. The results showed that inhibiting PCSK9 could significantly downregulate the protein expression of tissue factor (TF) in ECs to reduce the area of atherosclerotic plaques. In vitro, we incubated human umbilical vein endothelial cells (HUVECs) with lipopolysaccharide (LPS). We found that LPS-induced TF elevation was suppressed by a PCSK9 inhibitor at both the mRNA and protein levels and that the TLR4/NF-κB pathway was also suppressed by a PCSK9 inhibitor. With respect to plasma samples from patients with carotid artery stenosis, we also demonstrated that the expression of TF was positively correlated with that of PCSK9. Thus, in addition to regulating lipid metabolism, the regulation of endothelial cell TF expression through the TLR4/NF-κB pathway may be a potential mechanism of PCSK9 in promoting atherosclerotic carotid stenosis.
ArticleNumber 116314
Author Yang, Xin-yu
Jiang, Yu-hang
Zhang, Heng-rui
Li, Tian-xing
Peng, Chao
Chen, Yan
Zhao, Yan
Li, Jian
Author_xml – sequence: 1
  givenname: Chao
  surname: Peng
  fullname: Peng, Chao
  email: pengchao3892@163.com
– sequence: 2
  givenname: Jian
  surname: Li
  fullname: Li, Jian
  email: lijian1011s@tmu.edu.cn
– sequence: 3
  givenname: Yan
  surname: Chen
  fullname: Chen, Yan
  email: chenyan19998@163.com
– sequence: 4
  givenname: Heng-rui
  surname: Zhang
  fullname: Zhang, Heng-rui
  email: zhanghengrui@tmu.edu.cn
– sequence: 5
  givenname: Tian-xing
  surname: Li
  fullname: Li, Tian-xing
  email: ltxsmm@163.com
– sequence: 6
  givenname: Yu-hang
  surname: Jiang
  fullname: Jiang, Yu-hang
  email: jiangbao@tmu.edu.cn
– sequence: 7
  givenname: Xin-yu
  surname: Yang
  fullname: Yang, Xin-yu
  email: yangxinyu@tmu.edu.cn
– sequence: 8
  givenname: Yan
  surname: Zhao
  fullname: Zhao, Yan
  email: tjmuzhaoyan@163.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38797271$$D View this record in MEDLINE/PubMed
BookMark eNp9kUFuEzEUhi1URNPCAdggL9lMYnsmHlusStRSRAQIytp6Y79JHU3Gg-0EchLu0kNwJiZNYcGiK9vS9z09__8ZOelDj4S85GzKGZez9bSxw1QwUU05lyWvnpAJV3VZCC3VCZkwxuR4n4tTcpbS-vBUkj8jp6WqdS1qPiG_Pi--ftAUVqsIO8joqIUYsncUYsa4pyljH5JP1Pf0YgiXxaygG2-RNns6xLAZ2X5F8y1S_DlETMmHnoaWZp_SFmkLNod4b2Pvwsh1HjpqsesS3Xm4N2-WX6rZx6vi991bOkC-_QH75-RpC13CFw_nOfl2dXmzuC6Wn969X1wsCyukyoVlcwZC1rKtGye0blWJNei50lIKlK5sSqVBtQ0D69pStMohCK6d5bwSjpXn5PVx7viX71tM2Wx8OmwHPYZtMiWTrJ6LSukRffWAbpsNOjNEv4G4N3_DHAF-BGwMKUVs_yGcmUNhZm3GwsyhMHMsbHTq_xzrM-QxxBzBd4-ab44mjvHsPEaTrMfeovMRbTYu-EfsPxfhsKM
CitedBy_id crossref_primary_10_1016_j_athplu_2024_12_004
crossref_primary_10_1111_apha_14272
crossref_primary_10_1016_j_metabol_2024_156064
Cites_doi 10.1001/jamanetworkopen.2019.11130
10.1172/JCI122440
10.1161/CIRCRESAHA.115.306301
10.3389/fimmu.2022.894789
10.1016/S1474-4422(21)00359-8
10.1038/s41569-019-0239-5
10.1161/CIRCULATIONAHA.105.567297
10.1093/cvr/cvz313
10.1160/TH14-05-0451
10.7150/thno.83914
10.3390/ijms20020405
10.1016/j.yjmcc.2018.11.018
10.1161/01.CIR.101.22.2651
10.1161/ATVBAHA.117.309846
10.1007/s11239-011-0585-6
10.3390/ijms222312640
10.1016/j.bbrc.2008.07.023
10.1161/01.CIR.91.3.619
10.3389/fcvm.2022.888390
10.1038/s41574-018-0110-5
10.1016/j.ejphar.2020.173422
10.1161/CIRCULATIONAHA.120.046290
10.1016/j.thromres.2012.06.007
10.1124/pharmrev.120.000096
10.1016/j.intimp.2023.111195
10.1210/endrev/bnab035
10.1161/CIRCULATIONAHA.121.056491
10.1016/j.atherosclerosis.2017.04.023
10.1161/01.CIR.0000015465.73933.3B
10.1161/JAHA.121.023328
ContentType Journal Article
Copyright 2024 Elsevier Inc.
Copyright © 2024 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2024 Elsevier Inc.
– notice: Copyright © 2024 Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.bcp.2024.116314
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-2968
ExternalDocumentID 38797271
10_1016_j_bcp_2024_116314
S0006295224002971
Genre Journal Article
GroupedDBID ---
--K
--M
-~X
.55
.GJ
.HR
.~1
0R~
1B1
1RT
1~.
1~5
23N
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
6J9
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AAXKI
AAXUO
AAYJJ
ABFNM
ABFRF
ABJNI
ABLJU
ABMAC
ABWVN
ABXDB
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACNCT
ACRLP
ACRPL
ADBBV
ADEZE
ADMUD
ADNMO
AEBSH
AEFWE
AEKER
AENEX
AFFNX
AFJKZ
AFKWA
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AHHHB
AI.
AIEXJ
AIKHN
AITUG
AJOXV
AKRWK
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
C45
CS3
DU5
EBS
EFJIC
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HMT
HVGLF
HZ~
IH2
IHE
J1W
K-O
KOM
L7B
LPU
M34
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SDF
SDG
SDP
SES
SEW
SPCBC
SPT
SSP
SSZ
T5K
TEORI
TWZ
VH1
WH7
WUQ
X7M
ZGI
ZXP
~G-
AATTM
AAYWO
AAYXX
ACVFH
ADCNI
AEIPS
AEUPX
AFPUW
AGCQF
AGQPQ
AGRNS
AIGII
AIIUN
AKBMS
AKYEP
ANKPU
APXCP
BNPGV
CITATION
SSH
CGR
CUY
CVF
ECM
EFKBS
EIF
NPM
7X8
EFLBG
ID FETCH-LOGICAL-c268t-c050a2676f7bd299f83e7a9589662e6d3b389a8fb0acdf32f8dea219dc1142d03
IEDL.DBID AIKHN
ISSN 0006-2952
1873-2968
IngestDate Fri Sep 05 00:43:55 EDT 2025
Mon Jul 21 06:05:59 EDT 2025
Tue Jul 01 02:23:49 EDT 2025
Thu Apr 24 23:01:06 EDT 2025
Sat Dec 21 15:59:43 EST 2024
IsPeerReviewed true
IsScholarly true
Keywords LDL-C
Tissue factor
PCSK9
Proprotein convertase subtilisin/kexin type 9
LPS
Endothelial cells
TF
ECs
CAS
ND
Atherosclerosis
PL
Carotid artery stenosis
HUVECs
CID
Language English
License Copyright © 2024 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c268t-c050a2676f7bd299f83e7a9589662e6d3b389a8fb0acdf32f8dea219dc1142d03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 38797271
PQID 3060752489
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3060752489
pubmed_primary_38797271
crossref_primary_10_1016_j_bcp_2024_116314
crossref_citationtrail_10_1016_j_bcp_2024_116314
elsevier_sciencedirect_doi_10_1016_j_bcp_2024_116314
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate July 2024
2024-07-00
2024-Jul
20240701
PublicationDateYYYYMMDD 2024-07-01
PublicationDate_xml – month: 07
  year: 2024
  text: July 2024
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Biochemical pharmacology
PublicationTitleAlternate Biochem Pharmacol
PublicationYear 2024
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Li, He, Lv, Liu, Lv, Zhang, Zhu, Ai (b0090) 2019; 129
Bonati, Jansen, de Borst, Brown (b0005) 2022; 21
Gimbrone, Garcia-Cardena (b0120) 2016; 118
Wang, Li, Zhao, Liu, Tan, Xing, Adi, Wang, Fu, Ma, Liu, Liu, Wang, Shi, Lu, Song, Luo (b0100) 2022; 145
Steffel, Luscher, Tanner (b0025) 2006; 113
Zheng, Zhu, Li, Xu, Zhang (b0105) 2024; 126
Lee, Park, Hwang, Lee, Park, Kang, Lee, Kim, Park, Park (b0030) 2011; 32
Eto, Kozai, Cosentino, Joch, Luscher (b0150) 2002; 105
Cirillo, Ziviello, Pellegrino, Conte, Cimmino, Giaquinto, Pacifico, Leonardi, Golino, Trimarco (b0045) 2015; 113
Seidah, Prat (b0065) 2022; 43
Liu, Ma, Ma, Liu, Zhang, Zhang, Ni (b0140) 2019; 127
Grover, Mackman (b0020) 2018; 38
Stoekenbroek, Lambert, Cariou, Hovingh (b0055) 2018; 15
Souilhol, Serbanovic-Canic, Fragiadaki, Chico, Ridger, Roddie, Evans (b0015) 2020; 17
Annex, Denning, Channon, Sketch, Stack, Morrissey, Peters (b0035) 1995; 91
Cirillo, Di Palma, Maresca, Pacifico, Ziviello, Bevilacqua, Trimarco, Leonardi, Chiariello (b0145) 2012; 130
Hasenstab, Lea, Hart, Lok, Clowes (b0050) 2000; 101
Hao, Pang, Du, Lai, Chen, Xie, Zhou, Hou, Hsiao, Deng (b0155) 2019; 20
Liu, Wu, Stolarz, Zhang, Boerma, Byrum, Rusch, Ding (b0070) 2023; 13
Howe, Cybulsky, Fish (b0115) 2022; 9
Cimmino, Morello, Conte, Pellegrino, Marra, Golino, Cirillo (b0040) 2020; 885
Ding, Pothineni, Goel, Luscher, Mehta (b0080) 2020; 116
Feingold, Moser, Shigenaga, Patzek, Grunfeld (b0130) 2008; 374
Xu, Ilyas, Little, Li, Kamato, Zheng, Luo, Li, Liu, Han, Harding, Ebong, Cameron, Stewart, Weng (b0010) 2021; 73
Scalise, Sanguinetti, Neri, Cianchetti, Lai, Carnicelli, Celi, Pedrinelli (b0110) 2021; 22
Zou, Chen, Zhang, Yu, Xu, Cui, Li, Niu, Zhou, Xia, Wu (b0095) 2022; 13
Qi, Hu, Zhang, Yang, Liu, Jia, Yao, Chang, Pan, Zhong, Luo, Yao, Sun, Qian, Ding, Ge (b0060) 2021; 143
Punch, Klein, Diaba-Nuhoho, Morawietz, Garelnabi (b0125) 2022; 11
Wang, Li, Guo, Chen, Jiang, Song (b0135) 2016; 13
Feng, Wei, Chaugai, Carranza Leon, Kawai, Carranza Leon, Jiang, Zhong, Liu, Ihegword, Shaffer, Linton, Chung, Stein (b0075) 2019; 2
Tang, Peng, Ren, Yang, Li, Li, Wang, Wei, Liu, Zheng, Jiang (b0085) 2017; 262
Grover (10.1016/j.bcp.2024.116314_b0020) 2018; 38
Stoekenbroek (10.1016/j.bcp.2024.116314_b0055) 2018; 15
Zheng (10.1016/j.bcp.2024.116314_b0105) 2024; 126
Cirillo (10.1016/j.bcp.2024.116314_b0045) 2015; 113
Ding (10.1016/j.bcp.2024.116314_b0080) 2020; 116
Cirillo (10.1016/j.bcp.2024.116314_b0145) 2012; 130
Liu (10.1016/j.bcp.2024.116314_b0070) 2023; 13
Cimmino (10.1016/j.bcp.2024.116314_b0040) 2020; 885
Feng (10.1016/j.bcp.2024.116314_b0075) 2019; 2
Xu (10.1016/j.bcp.2024.116314_b0010) 2021; 73
Bonati (10.1016/j.bcp.2024.116314_b0005) 2022; 21
Howe (10.1016/j.bcp.2024.116314_b0115) 2022; 9
Lee (10.1016/j.bcp.2024.116314_b0030) 2011; 32
Hao (10.1016/j.bcp.2024.116314_b0155) 2019; 20
Annex (10.1016/j.bcp.2024.116314_b0035) 1995; 91
Seidah (10.1016/j.bcp.2024.116314_b0065) 2022; 43
Zou (10.1016/j.bcp.2024.116314_b0095) 2022; 13
Wang (10.1016/j.bcp.2024.116314_b0135) 2016; 13
Gimbrone (10.1016/j.bcp.2024.116314_b0120) 2016; 118
Qi (10.1016/j.bcp.2024.116314_b0060) 2021; 143
Punch (10.1016/j.bcp.2024.116314_b0125) 2022; 11
Liu (10.1016/j.bcp.2024.116314_b0140) 2019; 127
Souilhol (10.1016/j.bcp.2024.116314_b0015) 2020; 17
Tang (10.1016/j.bcp.2024.116314_b0085) 2017; 262
Hasenstab (10.1016/j.bcp.2024.116314_b0050) 2000; 101
Eto (10.1016/j.bcp.2024.116314_b0150) 2002; 105
Steffel (10.1016/j.bcp.2024.116314_b0025) 2006; 113
Feingold (10.1016/j.bcp.2024.116314_b0130) 2008; 374
Wang (10.1016/j.bcp.2024.116314_b0100) 2022; 145
Li (10.1016/j.bcp.2024.116314_b0090) 2019; 129
Scalise (10.1016/j.bcp.2024.116314_b0110) 2021; 22
References_xml – volume: 43
  start-page: 558
  year: 2022
  end-page: 582
  ident: b0065
  article-title: The Multifaceted Biology of PCSK9
  publication-title: Endocr. Rev.
– volume: 129
  start-page: 1167
  year: 2019
  end-page: 1179
  ident: b0090
  article-title: c-Abl regulates YAPY357 phosphorylation to activate endothelial atherogenic responses to disturbed flow
  publication-title: J. Clin. Invest.
– volume: 126
  year: 2024
  ident: b0105
  article-title: PCSK9 inhibitor protects against ischemic cerebral injury by attenuating inflammation via the GPNMB/CD44 pathway
  publication-title: Int. Immunopharmacol.
– volume: 11
  start-page: e023328
  year: 2022
  ident: b0125
  article-title: Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis
  publication-title: J. Am. Heart Assoc.
– volume: 885
  year: 2020
  ident: b0040
  article-title: Vitamin D inhibits Tissue Factor and CAMs expression in oxidized low-density lipoproteins-treated human endothelial cells by modulating NF-kappaB pathway
  publication-title: Eur. J. Pharmacol.
– volume: 2
  start-page: e1911130
  year: 2019
  ident: b0075
  article-title: A genetic approach to the association between PCSK9 and sepsis
  publication-title: JAMA Netw. Open
– volume: 262
  start-page: 113
  year: 2017
  end-page: 122
  ident: b0085
  article-title: New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-kappaB pathway
  publication-title: Atherosclerosis
– volume: 21
  start-page: 273
  year: 2022
  end-page: 283
  ident: b0005
  article-title: Management of atherosclerotic extracranial carotid artery stenosis
  publication-title: Lancet Neurol.
– volume: 20
  year: 2019
  ident: b0155
  article-title: Peach kernel oil downregulates expression of tissue factor and reduces atherosclerosis in ApoE knockout Mice
  publication-title: Int. J. Mol. Sci.
– volume: 145
  start-page: 675
  year: 2022
  end-page: 687
  ident: b0100
  article-title: Ablation of plasma prekallikrein decreases low-density lipoprotein cholesterol by stabilizing low-density lipoprotein receptor and protects against atherosclerosis
  publication-title: Circulation
– volume: 13
  start-page: 2914
  year: 2023
  end-page: 2929
  ident: b0070
  article-title: PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging
  publication-title: Theranostics
– volume: 13
  start-page: 312
  year: 2016
  end-page: 315
  ident: b0135
  article-title: Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus
  publication-title: J. Geriatr. Cardiol.
– volume: 101
  start-page: 2651
  year: 2000
  end-page: 2657
  ident: b0050
  article-title: Tissue factor overexpression in rat arterial neointima models thrombosis and progression of advanced atherosclerosis
  publication-title: Circulation
– volume: 105
  start-page: 1756
  year: 2002
  end-page: 1759
  ident: b0150
  article-title: Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways
  publication-title: Circulation
– volume: 17
  start-page: 52
  year: 2020
  end-page: 63
  ident: b0015
  article-title: Endothelial responses to shear stress in atherosclerosis: a novel role for developmental genes
  publication-title: Nat. Rev. Cardiol.
– volume: 15
  start-page: 52
  year: 2018
  end-page: 62
  ident: b0055
  article-title: Inhibiting PCSK9 - biology beyond LDL control
  publication-title: Nat. Rev. Endocrinol.
– volume: 116
  start-page: 908
  year: 2020
  end-page: 915
  ident: b0080
  article-title: PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1
  publication-title: Cardiovasc. Res.
– volume: 113
  start-page: 363
  year: 2015
  end-page: 372
  ident: b0045
  article-title: The adipokine apelin-13 induces expression of prothrombotic tissue factor
  publication-title: Thromb. Haemost.
– volume: 38
  start-page: 709
  year: 2018
  end-page: 725
  ident: b0020
  article-title: Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis
  publication-title: Arterioscler. Thromb. Vasc. Biol.
– volume: 113
  start-page: 722
  year: 2006
  end-page: 731
  ident: b0025
  article-title: Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications
  publication-title: Circulation
– volume: 9
  year: 2022
  ident: b0115
  article-title: The endothelium as a hub for cellular communication in atherogenesis: is there directionality to the message?
  publication-title: Front Cardiovasc Med
– volume: 13
  year: 2022
  ident: b0095
  article-title: Targeting PCSK9 ameliorates graft vascular disease in mice by inhibiting NLRP3 inflammasome activation in vascular smooth muscle cells
  publication-title: Front. Immunol.
– volume: 91
  start-page: 619
  year: 1995
  end-page: 622
  ident: b0035
  article-title: Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes
  publication-title: Circulation
– volume: 127
  start-page: 1
  year: 2019
  end-page: 10
  ident: b0140
  article-title: Overexpression of tissue factor induced atherothrombosis in apolipoprotein E-/- mice via both enhanced plaque thrombogenicity and plaque instability
  publication-title: J. Mol. Cell. Cardiol.
– volume: 143
  start-page: 45
  year: 2021
  end-page: 61
  ident: b0060
  article-title: PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36
  publication-title: Circulation
– volume: 374
  start-page: 341
  year: 2008
  end-page: 344
  ident: b0130
  article-title: Inflammation stimulates the expression of PCSK9
  publication-title: Biochem. Biophys. Res. Commun.
– volume: 118
  start-page: 620
  year: 2016
  end-page: 636
  ident: b0120
  article-title: Endothelial cell dysfunction and the pathobiology of atherosclerosis
  publication-title: Circ. Res.
– volume: 73
  start-page: 924
  year: 2021
  end-page: 967
  ident: b0010
  article-title: Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies
  publication-title: Pharmacol. Rev.
– volume: 130
  start-page: 403
  year: 2012
  end-page: 408
  ident: b0145
  article-title: The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: another piece in the adipokines puzzle
  publication-title: Thromb. Res.
– volume: 32
  start-page: 150
  year: 2011
  end-page: 157
  ident: b0030
  article-title: Comparison of ruptured coronary plaques in patients with unstable and stable clinical presentation
  publication-title: J. Thromb. Thrombolysis
– volume: 22
  year: 2021
  ident: b0110
  article-title: PCSK9 induces tissue factor expression by activation of TLR4/NFkB signaling
  publication-title: Int. J. Mol. Sci.
– volume: 2
  start-page: e1911130
  year: 2019
  ident: 10.1016/j.bcp.2024.116314_b0075
  article-title: A genetic approach to the association between PCSK9 and sepsis
  publication-title: JAMA Netw. Open
  doi: 10.1001/jamanetworkopen.2019.11130
– volume: 129
  start-page: 1167
  year: 2019
  ident: 10.1016/j.bcp.2024.116314_b0090
  article-title: c-Abl regulates YAPY357 phosphorylation to activate endothelial atherogenic responses to disturbed flow
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI122440
– volume: 118
  start-page: 620
  year: 2016
  ident: 10.1016/j.bcp.2024.116314_b0120
  article-title: Endothelial cell dysfunction and the pathobiology of atherosclerosis
  publication-title: Circ. Res.
  doi: 10.1161/CIRCRESAHA.115.306301
– volume: 13
  year: 2022
  ident: 10.1016/j.bcp.2024.116314_b0095
  article-title: Targeting PCSK9 ameliorates graft vascular disease in mice by inhibiting NLRP3 inflammasome activation in vascular smooth muscle cells
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2022.894789
– volume: 21
  start-page: 273
  year: 2022
  ident: 10.1016/j.bcp.2024.116314_b0005
  article-title: Management of atherosclerotic extracranial carotid artery stenosis
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(21)00359-8
– volume: 17
  start-page: 52
  year: 2020
  ident: 10.1016/j.bcp.2024.116314_b0015
  article-title: Endothelial responses to shear stress in atherosclerosis: a novel role for developmental genes
  publication-title: Nat. Rev. Cardiol.
  doi: 10.1038/s41569-019-0239-5
– volume: 113
  start-page: 722
  year: 2006
  ident: 10.1016/j.bcp.2024.116314_b0025
  article-title: Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.105.567297
– volume: 13
  start-page: 312
  year: 2016
  ident: 10.1016/j.bcp.2024.116314_b0135
  article-title: Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus
  publication-title: J. Geriatr. Cardiol.
– volume: 116
  start-page: 908
  year: 2020
  ident: 10.1016/j.bcp.2024.116314_b0080
  article-title: PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1
  publication-title: Cardiovasc. Res.
  doi: 10.1093/cvr/cvz313
– volume: 113
  start-page: 363
  year: 2015
  ident: 10.1016/j.bcp.2024.116314_b0045
  article-title: The adipokine apelin-13 induces expression of prothrombotic tissue factor
  publication-title: Thromb. Haemost.
  doi: 10.1160/TH14-05-0451
– volume: 13
  start-page: 2914
  year: 2023
  ident: 10.1016/j.bcp.2024.116314_b0070
  article-title: PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging
  publication-title: Theranostics
  doi: 10.7150/thno.83914
– volume: 20
  year: 2019
  ident: 10.1016/j.bcp.2024.116314_b0155
  article-title: Peach kernel oil downregulates expression of tissue factor and reduces atherosclerosis in ApoE knockout Mice
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms20020405
– volume: 127
  start-page: 1
  year: 2019
  ident: 10.1016/j.bcp.2024.116314_b0140
  article-title: Overexpression of tissue factor induced atherothrombosis in apolipoprotein E-/- mice via both enhanced plaque thrombogenicity and plaque instability
  publication-title: J. Mol. Cell. Cardiol.
  doi: 10.1016/j.yjmcc.2018.11.018
– volume: 101
  start-page: 2651
  year: 2000
  ident: 10.1016/j.bcp.2024.116314_b0050
  article-title: Tissue factor overexpression in rat arterial neointima models thrombosis and progression of advanced atherosclerosis
  publication-title: Circulation
  doi: 10.1161/01.CIR.101.22.2651
– volume: 38
  start-page: 709
  year: 2018
  ident: 10.1016/j.bcp.2024.116314_b0020
  article-title: Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis
  publication-title: Arterioscler. Thromb. Vasc. Biol.
  doi: 10.1161/ATVBAHA.117.309846
– volume: 32
  start-page: 150
  year: 2011
  ident: 10.1016/j.bcp.2024.116314_b0030
  article-title: Comparison of ruptured coronary plaques in patients with unstable and stable clinical presentation
  publication-title: J. Thromb. Thrombolysis
  doi: 10.1007/s11239-011-0585-6
– volume: 22
  year: 2021
  ident: 10.1016/j.bcp.2024.116314_b0110
  article-title: PCSK9 induces tissue factor expression by activation of TLR4/NFkB signaling
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms222312640
– volume: 374
  start-page: 341
  year: 2008
  ident: 10.1016/j.bcp.2024.116314_b0130
  article-title: Inflammation stimulates the expression of PCSK9
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2008.07.023
– volume: 91
  start-page: 619
  year: 1995
  ident: 10.1016/j.bcp.2024.116314_b0035
  article-title: Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes
  publication-title: Circulation
  doi: 10.1161/01.CIR.91.3.619
– volume: 9
  year: 2022
  ident: 10.1016/j.bcp.2024.116314_b0115
  article-title: The endothelium as a hub for cellular communication in atherogenesis: is there directionality to the message?
  publication-title: Front Cardiovasc Med
  doi: 10.3389/fcvm.2022.888390
– volume: 15
  start-page: 52
  year: 2018
  ident: 10.1016/j.bcp.2024.116314_b0055
  article-title: Inhibiting PCSK9 - biology beyond LDL control
  publication-title: Nat. Rev. Endocrinol.
  doi: 10.1038/s41574-018-0110-5
– volume: 885
  year: 2020
  ident: 10.1016/j.bcp.2024.116314_b0040
  article-title: Vitamin D inhibits Tissue Factor and CAMs expression in oxidized low-density lipoproteins-treated human endothelial cells by modulating NF-kappaB pathway
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2020.173422
– volume: 143
  start-page: 45
  year: 2021
  ident: 10.1016/j.bcp.2024.116314_b0060
  article-title: PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.120.046290
– volume: 130
  start-page: 403
  year: 2012
  ident: 10.1016/j.bcp.2024.116314_b0145
  article-title: The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: another piece in the adipokines puzzle
  publication-title: Thromb. Res.
  doi: 10.1016/j.thromres.2012.06.007
– volume: 73
  start-page: 924
  year: 2021
  ident: 10.1016/j.bcp.2024.116314_b0010
  article-title: Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies
  publication-title: Pharmacol. Rev.
  doi: 10.1124/pharmrev.120.000096
– volume: 126
  year: 2024
  ident: 10.1016/j.bcp.2024.116314_b0105
  article-title: PCSK9 inhibitor protects against ischemic cerebral injury by attenuating inflammation via the GPNMB/CD44 pathway
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2023.111195
– volume: 43
  start-page: 558
  year: 2022
  ident: 10.1016/j.bcp.2024.116314_b0065
  article-title: The Multifaceted Biology of PCSK9
  publication-title: Endocr. Rev.
  doi: 10.1210/endrev/bnab035
– volume: 145
  start-page: 675
  year: 2022
  ident: 10.1016/j.bcp.2024.116314_b0100
  article-title: Ablation of plasma prekallikrein decreases low-density lipoprotein cholesterol by stabilizing low-density lipoprotein receptor and protects against atherosclerosis
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.121.056491
– volume: 262
  start-page: 113
  year: 2017
  ident: 10.1016/j.bcp.2024.116314_b0085
  article-title: New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-kappaB pathway
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2017.04.023
– volume: 105
  start-page: 1756
  year: 2002
  ident: 10.1016/j.bcp.2024.116314_b0150
  article-title: Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways
  publication-title: Circulation
  doi: 10.1161/01.CIR.0000015465.73933.3B
– volume: 11
  start-page: e023328
  year: 2022
  ident: 10.1016/j.bcp.2024.116314_b0125
  article-title: Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis
  publication-title: J. Am. Heart Assoc.
  doi: 10.1161/JAHA.121.023328
SSID ssj0006861
Score 2.4682739
Snippet [Display omitted] Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play...
Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play a significant...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 116314
SubjectTerms Animals
Apolipoproteins E - deficiency
Apolipoproteins E - genetics
Apolipoproteins E - metabolism
Atherosclerosis
Carotid artery stenosis
Carotid Stenosis - metabolism
Endothelial cells
Endothelial Cells - drug effects
Endothelial Cells - metabolism
Female
Human Umbilical Vein Endothelial Cells - metabolism
Humans
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Mice, Knockout, ApoE
NF-kappa B - metabolism
PCSK9 Inhibitors
Proprotein Convertase 9 - genetics
Proprotein Convertase 9 - metabolism
Proprotein convertase subtilisin/kexin type 9
Signal Transduction - physiology
Thromboplastin - biosynthesis
Thromboplastin - genetics
Thromboplastin - metabolism
Tissue factor
Toll-Like Receptor 4 - genetics
Toll-Like Receptor 4 - metabolism
Title PCSK9 aggravated carotid artery stenosis in ApoE-/- mice by promoting the expression of tissue factors in endothelial cells via the TLR4/NF-κB pathway
URI https://dx.doi.org/10.1016/j.bcp.2024.116314
https://www.ncbi.nlm.nih.gov/pubmed/38797271
https://www.proquest.com/docview/3060752489
Volume 225
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELbK9gAXBOWny081SKgHVLNZ23Hi47LqaqFotYKt1FvkxE4VVCUrNm3JhdfgXXgInolx4mzFoT1wTJRRLI8981n-Zj5C3mJOzVgkBWUyVFRobqkWMqRcxO7WKFIma1m-Czk_FZ_OwrMdMu1rYRyt0sf-Lqa30dq_GfnZHK2LwtX4BpKpsGVBMuXqyHcZVzIckN3Jx5P5YhuQZSy9cJ6kzqC_3GxpXmnmulYygbFD8rG4LT3dBj_bNDR7RB56_AiTboiPyY4t98j9aS_btkcOl10z6uYIVje1VZsjOITlTZvq5gn5tZx-PVGgz50CESJOA07Cpy4MtDTPBtD_ZbUpNlCUMFlXx3REwYnXQ9rAumPxleeAABLsD0-nLaHKoW59CV7Jx1nb0rhCrwtc6-BuCjZwVejWcvX5ixgtZvTP7w_gxJGvdfOUnM6OV9M59TINNGMyrmkWhIFmMpJ5lBrMbnnMbaRVGONJillpeIqgSMd5GujM5JzlsbEaA6XJXB2vCfgzMiir0u4TiCzCj9iqwGZSGK3T0CoR8TyVKZ6LuBmSoPdOkvke5k5K4yLpyWrfEnRo4hyadA4dkndbk3XXwOOuj0Xv8uSfVZhggrnL7E2_PBL0tptIXdrqcpPggQwxGROxGpLn3brZjoLjTkD0OH7xfz99SR64p446_IoM6u-X9jUCpDo9IPfe_xwf-G3wF9EHDnk
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELaqcigXBOVvKT-DhHpANZvajpMcy6qrhS6rFWyl3iw7dqqgKlmRtJALr8G78BA8E-P8dMWhPXBNYsXyjGc-y9_MR8gbzKkpi6SgTIYJFZo7qoUMKRexvzWKEpu2LN-FnJ2Kj2fh2RaZDLUwnlbZx_4uprfRun8y7ldzvM5zX-MbSJaELQuSJb6O_I4IeeR5fe9-bngeMpa9bJ6k_vPharMleZnU96xkAiOH5IfipuR0E_hsk9D0PrnXo0c46ib4gGy5YpfsTAbRtl2yv-xaUTcHsNpUVlUHsA_LTZPq5iH5tZx8OUlAn3v9IcSbFryAT51baEmeDaD1i7LKK8gLOFqXx3RMwUvXg2lg3XH4inNA-AjuR0-mLaDMoG4tCb2Ojx_tCuvLvC7Q08HfE1Rwlet25Gr-WYwXU_rn93vw0sjfdfOInE6PV5MZ7UUaaMpkXNM0CAPNZCSzyFjMbVnMXaSTMMZzFHPScoOQSMeZCXRqM86y2DqNYdKmvorXBvwx2S7Kwj0lEDkEH7FLApdKYbU2oUtExDMjDZ6KuB2RYLCOSvsO5l5I40INVLWvCg2qvEFVZ9AReXs9ZN2177jtYzGYXP3jgwrTy23DXg_uodDafiF14crLSuFxDBEZE3EyIk86v7meBcd9gNjx8Nn__fQV2ZmtPs3V_MPiZI_c9W86EvFzsl1_u3QvECrV5mW7Ff4CHjAPRA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PCSK9+aggravated+carotid+artery+stenosis+in+ApoE-%2F-+mice+by+promoting+the+expression+of+tissue+factors+in+endothelial+cells+via+the+TLR4%2FNF-%CE%BAB+pathway&rft.jtitle=Biochemical+pharmacology&rft.au=Peng%2C+Chao&rft.au=Li%2C+Jian&rft.au=Chen%2C+Yan&rft.au=Zhang%2C+Heng-rui&rft.date=2024-07-01&rft.issn=0006-2952&rft.volume=225&rft.spage=116314&rft_id=info:doi/10.1016%2Fj.bcp.2024.116314&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_bcp_2024_116314
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-2952&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-2952&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-2952&client=summon